Read More

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint Of Progression-Free Survival For Patients With Pretreated KRASG12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or

BMY

Read More

Extend Life Expectancy Against Aggressive Brain Cancers – Nano-Cap Firm Biodexa’s Investigational Drug Shows Potential

Biodexa Pharmaceuticals' MTX110, revolutionizing brain cancer treatment with innovative drug delivery technology. Early trials show promising survival rate extensions in Diffuse Midline Glioma and Recurrent Glioblastoma patients. Learn more about MTX110's potential.

BDRX

Read More

Insurance Coverage For Weight Loss Drugs – Elevance, CVS Health Become First To Extend Coverage To Novo Nordisk’s Successful Wegovy For Certain Patients

Major U.S. health insurers CVS Health, Elevance Health, and Kaiser Permanente now reimburse for Novo Nordisk's Wegovy for specific Medicare individuals with heart-related conditions. This shift aims to alleviate financial burden and may prompt broader coverage, potentially impacting drug spending.

CVS